Medigene Limited
Records under this name other than patents Medigene Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,816,361 | Immuno inhibitory pyrazolone compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,361,794 | Cells Expressing a Modified T Cell Receptor Formerly held In force · High confidence | In force | High confidence | |
| US 11,440,944 | Engineered Immune-Mobilizing T-Cell Receptors with Enhanced Affinity for HIV-1 Gag Formerly held In force · High confidence | In force | High confidence | |
| US 7,932,253 | Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors Formerly held Term ended Term ended Aug 23, 2025 · From the USPTO record | Term ended | Term ended Aug 23, 2025 | From the USPTO record |
| US 8,008,438 | High Affinity Ny-Eso T Cell Receptors Formerly held Term ended Term ended May 18, 2025 · High confidence | Term ended | Term ended May 18, 2025 | High confidence |
| US 8,143,376 | High Affinity Ny-Eso T Cell Receptor Formerly held Term ended Term ended May 18, 2025 · High confidence | Term ended | Term ended May 18, 2025 | High confidence |
| US 8,367,804 | High Affinity Ny-Eso T Cell Receptors Formerly held Term ended Term ended May 18, 2025 · High confidence | Term ended | Term ended May 18, 2025 | High confidence |
| US 9,156,903 | High Affinity Ny-Eso T Cell Receptors Formerly held Term ended Term ended May 18, 2025 · High confidence | Term ended | Term ended May 18, 2025 | High confidence |
| US 9,512,197 | High Affinity Ny-Eso T Cell Receptors Formerly held Term ended Term ended May 18, 2025 · High confidence | Term ended | Term ended May 18, 2025 | High confidence |
| US 9,822,163 | High Affinity Ny-Eso T Cell Receptors Formerly held Term ended Term ended May 18, 2025 · High confidence | Term ended | Term ended May 18, 2025 | High confidence |